Challenging issues in neonatal candidiasis

References

• Kaufman DA. Neonatal candidiasis: clinical manifestations, management, and prevention strategies. J Pediatr 2010;156:S47-52
   Web of Science ®Google Scholar
• Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91
   PubMed Web of Science ®Google Scholar
• Guida JD, Kunig AM, Leef KH, et al. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response?. Pediatrics 2003;111:1411-15
   PubMed Web of Science ®Google Scholar
• Manzoni P, Mostert M, Galletto P, et al. Is thrombocytopenia suggestive of organism-specific response in neonatal sepsis?. Pediatr Int 2009;51:206-10
   PubMed Web of Science ®Google Scholar
• Bhat MA, Bhat JI, Kawoosa MS, et al. Organism-specific platelet response and factors affecting survival in thrombocytopenic very low birth weight babies with sepsis. J Perinatol 2009;29:702-8
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, DeLong ER, Steinbach WJ, et al. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003;112:543-7
   PubMed Web of Science ®Google Scholar
• Makhoul IR, Kassis I, Smolkin T, et al. Review of 49 neonates with acquired fungal sepsis: further characterization. Pediatrics 2001;107:61-6
   PubMed Web of Science ®Google Scholar
• Procianoy RS, Eneas MV, Silveira RC. Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr 2006;165:422-3
   PubMed Web of Science ®Google Scholar
• Schelonka RL, Moser SA. Time to positive culture results in neonatal Candida septicemia. J Pediatr 2003;142:564-5
   PubMed Web of Science ®Google Scholar
• Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10
   PubMed Web of Science ®Google Scholar
• Baley JE. Neonatal candidiasis: the current challenge. Clin Perinatol 1991;18:263-80
   PubMed Web of Science ®Google Scholar
• Candidiasis. In: Pickering L, Kimberlin DW, Baker CJ, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2009:245-9
   Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7
   PubMed Web of Science ®Google Scholar
• Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7
   PubMedGoogle Scholar
• Yalaz M, Akisu M, Hilmioglu S, et al. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006;49:242-5
   PubMed Web of Science ®Google Scholar
• Smith PB, Steinbach WJ, Cotten CM, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007;27:127-9
   PubMed Web of Science ®Google Scholar
• Natale F, Castronovo A, Regoli D, et al. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr Infect Dis J 2009;28:452
   PubMed Web of Science ®Google Scholar
• Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52:4043-9
   PubMed Web of Science ®Google Scholar
• Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009;28:717-23
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28:412-15
   PubMed Web of Science ®Google Scholar
• King KY, Edwards MS, Word BM. Hepatitis associated with micafungin use in a preterm infant. J Perinatol 2009;29:320-2
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75
   PubMed Web of Science ®Google Scholar
• Le J, Adler-Shohet FC, Nguyen C, et al. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009;28:1061-3
   PubMed Web of Science ®Google Scholar
• Holler B, Omar SA, Farid MD, et al. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004;113:e608-6
   PubMed Web of Science ®Google Scholar
• Turcu R, Patterson MJ, Omar S. Influence of sodium intake on amphotericin B-induced nephrotoxicity among extremely premature infants. Pediatr Nephrol 2009;24:497-505
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005;49:5092-8
   PubMed Web of Science ®Google Scholar
• Kotwani RN, Gokhale PC, Bodhe PV, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm 2002;238:11-15
   PubMed Web of Science ®Google Scholar
• Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009;29:738-43
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87:93-9
   PubMed Web of Science ®Google Scholar
• Silva AP, Miranda IM, Lisboa C, et al. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C.orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009;47:2392-7
   PubMed Web of Science ®Google Scholar
• Jeon GW, Koo SH, Lee JH, et al. A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J 2007;48:619-26
   PubMed Web of Science ®Google Scholar
• Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003;22:603-7
   PubMed Web of Science ®Google Scholar
• Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52:663-7
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1–>3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother 2008;52:4121-9
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197:163-71
   PubMed Web of Science ®Google Scholar
• Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000;19:822-7
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92
   PubMed Web of Science ®Google Scholar
• Kaufman DA. Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU?. Curr Opin Pediatr 2008;20:332-40
   PubMed Web of Science ®Google Scholar
• Waggoner-Fountain LA, Walker MW, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996;22:803-8
   PubMed Web of Science ®Google Scholar
• Freydiere AM, Piens MA, Andre JM, et al. Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization. Eur J Clin Microbiol Infect Dis 2005;24:704-5
   PubMed Web of Science ®Google Scholar
• Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004;17:638-80
   PubMed Web of Science ®Google Scholar
• Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006;118:717-22
   PubMed Web of Science ®Google Scholar
• Makhoul IR, Bental Y, Weisbrod M, et al. Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J Hosp Infect 2007;65:237-43
   PubMed Web of Science ®Google Scholar
• Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000;19:319-24
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Temprosa M, Tyson JE, et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics 1999;104:e63
   PubMed Web of Science ®Google Scholar
• Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57
   PubMed Web of Science ®Google Scholar
• Noyola DE, Fernandez M, Moylett EH, et al. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001;32:1018-23
   PubMed Web of Science ®Google Scholar
• Aly H, Herson V, Duncan A, et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics 2005;115:1513-18
   PubMed Web of Science ®Google Scholar
• Garland JS, Henrickson K, Maki DG. The 2002 Hospital Infection Control Practices Advisory Committee Centers for Disease Control and Prevention guideline for prevention of intravascular device-related infection. Pediatrics 2002;110:1009-13
   PubMed Web of Science ®Google Scholar
• Curry S, Honeycutt M, Goins G, et al. Catheter-associated bloodstream infections in the NICU: getting to zero. Neonatal Netw 2009;28:151-5
   PubMedGoogle Scholar
• Schulman J, Wirtschafter DD, Kurtin P. Neonatal intensive care unit collaboration to decrease hospital-acquired bloodstream infections: from comparative performance reports to improvement networks. Pediatr Clin North Am 2009;56:865-92
   PubMed Web of Science ®Google Scholar
• Schulman J, Stricof RL, Stevens TP, et al. Development of a statewide collaborative to decrease NICU central line-associated bloodstream infections. J Perinatol 2009;29:591-9
   PubMed Web of Science ®Google Scholar
• Garland JS, Uhing MR. Strategies to prevent bacterial and fungal infection in the neonatal intensive care unit. Clin Perinatol 2009;36:1-13
   PubMed Web of Science ®Google Scholar
• Garland JS, Alex CP, Mueller CD, et al. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics 2001;107:1431-6
   PubMed Web of Science ®Google Scholar
• Visscher M, deCastro MV, Combs L, et al. Effect of chlorhexidine gluconate on the skin integrity at PICC line sites. J Perinatol 2009;29:802-7
   PubMed Web of Science ®Google Scholar
• Garland JS, Alex CP, Uhing MR, et al. Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheter placement in neonates. J Perinatol 2009;29:808-13
   PubMed Web of Science ®Google Scholar
• Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6
   PubMed Web of Science ®Google Scholar
• Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001;107:293-8
   PubMed Web of Science ®Google Scholar
• Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for the prevention of candidemia in preterm infants <1000 grams. J Pediatr 2005;147:172-9
   PubMed Web of Science ®Google Scholar
• Bertini G, Perugi S, Dani C, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005;147:162-5
   PubMed Web of Science ®Google Scholar
• Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005;147:166-71
   PubMed Web of Science ®Google Scholar
• Manzoni P, Arisio R, Mostert M, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006;117:e22-32
   PubMed Web of Science ®Google Scholar
• Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006;117:1243-52
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006;26:550-5
   PubMed Web of Science ®Google Scholar
• Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95
   PubMed Web of Science ®Google Scholar
• Weitkamp JH, Ozdas A, Lafleur B, et al. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008;28:405-11
   PubMed Web of Science ®Google Scholar
• Aziz M, Patel AL, Losavio J, et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010;29:352-6.
   Google Scholar
• Violaris K, Carbone T, Bateman D, et al. Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 2010;27:73-8
   PubMed Web of Science ®Google Scholar
• Johnsson H, Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23–28 weeks is inversely correlated to gestational age. Acta Paediatr 2004;93:954-8
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004;292:2357-65
   PubMed Web of Science ®Google Scholar
• Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008;27:731-7
   PubMed Web of Science ®Google Scholar
• Sims ME, Yoo Y, You H, et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988;5:33-6
   PubMed Web of Science ®Google Scholar
• Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006;49:484-92
   PubMed Web of Science ®Google Scholar
• Ganesan K, Harigopal S, Neal T, et al. Prophylactic oral nystatin for preterm babies under 33 weeks gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009;94:F275-8
   PubMed Web of Science ®Google Scholar
• Howell AJ, Isaacs D, Halliday R. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009;94:F429-33
   PubMed Web of Science ®Google Scholar
• Jew RK, Owen D, Kaufman D, et al. Osmolality of commonly used medications and formulas in the neonatal intensive care unit. Nutr Clin Pract 1997;12:158-63
   Google Scholar
• Ernst JA, Williams JM, Glick MR, et al. Osmolality of substances used in the intensive care nursery. Pediatrics 1983;72:347-52
   PubMed Web of Science ®Google Scholar
• Mutz AE, Obladen MW. Hyperosmolar oral medication and necrotizing enterocolitis. Pediatrics 1985;75:371-2
   PubMed Web of Science ®Google Scholar
• Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics 2008;122:1158-9
   PubMed Web of Science ®Google Scholar
• Isaacs D. Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing?. Curr Opin Infect Dis 2008;21:246-50
   PubMed Web of Science ®Google Scholar